Published: 1 October 2022
Author(s): Michael Nolde, Nayeon Ahn, Tobias Dreischulte, Evamaria Krause, Florian Güntner, Alexander Günter, Roman Gerlach, Martin Tauscher, Ute Amann, Jakob Linseisen, Christa Meisinger, Sebastian-Edgar Baumeister, Ina-Maria Rückert-Eheberg
Section: Original article

Proton pump inhibitors (PPIs) are widely used to treat disorders characterized by excessive gastric acid production [1] and have been sold over-the-counter for more than one decade. Alongside, PPIs are used for gastroprotection in patients on dual antiplatelet therapy consisting of asprin in combination with a P2Y12 inhibitor such as clopidogrel, prasugrel or ticagrelor to prevent secondary myocardial infarctions and ischaemic strokes. Two different questions, therefore, arise regarding a potentially increased cardiovascular risk associated with PPI intake.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.